Investors

Key press releases

03 Sep 2024
11:05 E.S.T.

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

26 Aug 2024
10:35 E.S.T.

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

07 Aug 2024
02:00 E.S.T.

Corporate

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Key upcoming events

29 Oct 2024 ‐ 30 Oct 2024

Science In The Age Of Experience 2024

Learn more

03 Dec 2024

7th Annual Evercore ISI HealthCONx Conference

Learn more

Key corporate presentation

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

$2.0100

+0.0100 (0.5000%)

Prev. close: 2.0000
Volume: 16,645
High: 2.0400
Capitalization: 144.908M

€1.8660

+0.0040 (0.2148%)

Prev. close: 1.8620
Volume: 22,722
High: 1.8860
Capitalization: 134.527M

See stock information

Covering research analysts

Barclays - Gena Wang

Bryan Garnier - Oscar Haffen-Lamm

Citi - Yigal Nochomovitz

Goldman Sachs - Salveen Richter

Jefferies - Kelly Shi

JMP Securities - Silvan Tuerkcan

Jones Trading - Soumit Roy

Kempen - Sebastiaan van der Schoot

Oddo BHF - Martial Descoutures

RW Baird - Jack Allen

Wells Fargo – Yanan Zhu

Cellectis contact information

Arthur Stril, Interim Chief Financial Officer

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89